1. Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation
   Ozgecan Dulgar et al, 2019, Journal of Oncology Pharmacy Practice CrossRef
2. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions
   Makito Miyake et al, 2013, Journal of Hematology & Oncology CrossRef
3. Erythropoietin production in renal cell carcinoma and renal cysts in autosomal dominant polycystic kidney disease in a chronic dialysis patient with polycythemia: A case report
   KEIICHI ITO et al, 2014, Oncology Letters CrossRef
4. Role of the Renin–Angiotensin System Components in Renal Cell Carcinoma: A Literature Review
   Thiago Camelo Mourão et al, 2023, Current Urology Reports CrossRef
5. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins
   Tania Romina Stoyanoff et al, 2016, Tumor Biology CrossRef
6. Polycythemia with Renal Cell Carcinoma and Normal Erythropoietin Level
   Jonathan Kopel et al, 2019, Case Reports in Urology CrossRef
7. Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines
   YUTAKA FUJISUE et al, 2013, Oncology Letters CrossRef